Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

Christopher M. Rubino, Sujata M. Bhavnani, Jeffery S. Loutit, Brooke Lohse, Michael N. Dudley, David C. Griffith
Christopher M. Rubino
aInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujata M. Bhavnani
aInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffery S. Loutit
bThe Medicines Company, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brooke Lohse
bThe Medicines Company, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael N. Dudley
bThe Medicines Company, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Griffith
bThe Medicines Company, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02103-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

DOI 
https://doi.org/10.1128/AAC.02103-17
PubMed 
29311069

Published By 
American Society for Microbiology Journals
History 
  • Received October 11, 2017
  • Returned for modification November 5, 2017
  • Accepted December 18, 2017
  • Published online February 23, 2018.

Copyright & Usage 
Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Article Versions

  • Accepted Manuscript version (January 08, 2018).
  • You are viewing the most recent version of this article.

Author Information

  1. Christopher M. Rubinoa,
  2. Sujata M. Bhavnania,
  3. Jeffery S. Loutitb,
  4. Brooke Lohseb,
  5. Michael N. Dudleyb and
  6. David C. Griffithb
  1. aInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA
  2. bThe Medicines Company, San Diego, California, USA
  • Address correspondence to David C. Griffith, david.griffith{at}themedco.com.
  • Citation Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC. 2018. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother 62:e02103-17. https://doi.org/10.1128/AAC.02103-17.

View Abstract

Article usage

Article usage: January 2018 to January 2021

Rendering graph...
AbstractFullPdf
Jan 2018715038
Feb 2018319659
Mar 20183551738
Apr 201883817
May 2018711624
Jun 201850512
Jul 201864211
Aug 2018291924
Sep 201843021
Oct 201862821
Nov 201843315
Dec 201803513
Jan 201923617
Feb 201962722
Mar 201913212
Apr 201933012
May 201924720
Jun 201913212
Jul 201913018
Aug 201962428
Sep 201923925
Oct 20192354
Nov 201962621
Dec 201941713
Jan 202052514
Feb 2020336454
Mar 202043721
Apr 202054122
May 202037864
Jun 202034419
Jul 202025230
Aug 202053424
Sep 202054426
Oct 202024232
Nov 202013434
Dec 202063821
Jan 202112711
PreviousNext
Back to top
Download PDF
Citation Tools
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
Christopher M. Rubino, Sujata M. Bhavnani, Jeffery S. Loutit, Brooke Lohse, Michael N. Dudley, David C. Griffith
Antimicrobial Agents and Chemotherapy Feb 2018, 62 (3) e02103-17; DOI: 10.1128/AAC.02103-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
Christopher M. Rubino, Sujata M. Bhavnani, Jeffery S. Loutit, Brooke Lohse, Michael N. Dudley, David C. Griffith
Antimicrobial Agents and Chemotherapy Feb 2018, 62 (3) e02103-17; DOI: 10.1128/AAC.02103-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

meropenem-vaborbactam
pharmacokinetics
renal impairment
hemodialysis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596